Eli Lilly and Company $LLY Shares Acquired by ABN AMRO Bank N.V.

ABN AMRO Bank N.V. lifted its position in Eli Lilly and Company (NYSE:LLY) by 20.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 249,049 shares of the company’s stock after buying an additional 43,004 shares during the quarter. Eli Lilly and Company accounts for approximately 2.5% of ABN AMRO Bank N.V.’s portfolio, making the stock its 8th biggest position. ABN AMRO Bank N.V.’s holdings in Eli Lilly and Company were worth $267,207,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Maryland Capital Advisors Inc. purchased a new stake in Eli Lilly and Company during the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares during the period. 10Elms LLP boosted its stake in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 10 shares during the period. Miller Global Investments LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $33,000. Finally, Hopwood Financial Services Inc. increased its stake in Eli Lilly and Company by 113.6% during the 3rd quarter. Hopwood Financial Services Inc. now owns 47 shares of the company’s stock worth $36,000 after buying an additional 25 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Barclays raised its price target on Eli Lilly to $1,400 from $1,350 and kept an Overweight rating, reinforcing the market’s view that the company’s long-term growth story remains intact. Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)
• Positive Sentiment: Investor enthusiasm is also being supported by strong fundamental momentum, including recent commentary that Eli Lilly remains a top momentum stock and continued recognition of its growth profile after a major revenue beat. Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
• Positive Sentiment: Management highlighted strong sales performance, with CFO Lucas Montrace discussing what drove the company’s 56% year-over-year revenue increase, underscoring continued demand for Lilly’s drug portfolio. Eli Lilly CFO Lucas Montrace Explains What Drove 56% Year-over-Year Revenue Beat
• Positive Sentiment: News that Mounjaro has surpassed Merck’s Keytruda as the world’s best-selling drug highlights how quickly Lilly’s obesity and diabetes franchise has become a major earnings driver. Eli Lilly’s Mounjaro surpasses Merck’s Keytruda as best-selling drug
• Neutral Sentiment: Lilly also agreed to acquire Centessa Pharmaceuticals, and the deal is drawing legal scrutiny over price and process; this is a watch item rather than a clear catalyst for the stock. Centessa Pharmaceuticals Investor Alert
• Negative Sentiment: A Reuters report said Lilly halted its obesity awareness campaign in India after regulators questioned whether it could amount to indirect advertising for prescription drugs, adding a small regulatory overhang. Exclusive: Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Wall Street Analyst Weigh In

LLY has been the subject of several research reports. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 2nd. Rothschild & Co Redburn lifted their target price on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. CICC Research boosted their target price on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 11th. Wells Fargo & Company increased their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,218.33.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $965.85 on Tuesday. The stock has a market cap of $909.58 billion, a P/E ratio of 34.31, a price-to-earnings-growth ratio of 1.03 and a beta of 0.48. The company has a fifty day simple moving average of $941.13 and a 200-day simple moving average of $993.05. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts expect that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.